The Medicines and Healthcare products Regulatory Agency has announced the launch of a online reporting mechanism for monitoring the safety of the swine flu antiviral medicines.
It is expected that usage of oseltamivir (Tamiflu®) and zanamavir (Relenza®) will increase during the swine flu pandemic. The Swine 'Flu ADR Portal can be used by healthcare professionals and the public to reported suspected adverse drug reactions (ADR) to either of these drugs.
Action: Clinicians should be aware of this portal and recommend it to patients with suspected ADRs. Clinicians should report adverse events for patients without internet access.